-
Posted by
Two Blokes May 1 -
Filed in
Stock
-
5 views
SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.
